Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0225

Medical education · Dr. Tomoko Quinn

28 Feb 2026 · In person · Dr. Tomoko Quinn, Hospital Sírio-Libanês · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0225—

Capture insight from this engagement

Location: Hospital Sírio-Libanês
Therapeutic area: Neurology
Country: Brazil
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Switching between CGRP agents

Scientific content used

CGRP class review

Questions raised

Is there guidance on switching from a monoclonal antibody?
Any data in patients with medication-overuse headache?

Notes

Medical education with headache specialist at Hospital Sírio-Libanês. Discussed switching between cgrp agents.

Insights captured (1)

Capture insight

INS-0057Medium
Switching between CGRP agents
Switching between CGRP agents: request for data reported by headache specialist (BR).
Archived

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 3
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0225

Audit history (0)

All create, update and approval events for this record

No audit events in sample data